Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jan 24;17(1):15-18.
doi: 10.21037/jtd-24-1535. Epub 2025 Jan 20.

Could combination immunotherapy give light to resectable esophageal squamous cell carcinoma?

Kazuhiro Shiraishi  1 , Shun Yamamoto  1 , Hiroshi Imazeki  1 , Ken Kato  1
Affiliations
Editorial

Could combination immunotherapy give light to resectable esophageal squamous cell carcinoma?

Kazuhiro Shiraishi et al. J Thorac Dis. .
No abstract available

Keywords: Immune checkpoint inhibitor (ICI); neoadjuvant therapy; resectable esophageal squamous cell carcinoma (resectable ESCC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-1535/coif). S.Y. has received honoraria for lectures from Ono Pharmaceutical, Bristol-Myers Squibb, MSD, and Taiho Pharmaceutical (outside the submitted work). K.K. reports consulting fees from Bristol Myers Squibb and Merck Sharp & Dohme, BeiGene, Roche, AstraZeneca, and Bayer; honoraria from Ono Pharmaceuticals, Bristol Myers Squibb, and Taiho; research funding from Ono Pharmaceuticals, Bristol Myers Squibb, Merck Sharp & Dohme, BeiGene, Chugai, Shionogi, AstraZeneca, and Bayer for research subjects, outside the submitted work. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Qin J, Xue L, Hao A, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial. Nat Med 2024;30:2549-57. 10.1038/s41591-024-03064-w - DOI - PMC - PubMed
    1. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84. 10.1056/NEJMoa1112088 - DOI - PubMed
    1. Yang H, Liu H, Chen Y, et al. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol 2018;36:2796-803. 10.1200/JCO.2018.79.1483 - DOI - PMC - PubMed
    1. Tang H, Wang H, Fang Y, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann Oncol 2023;34:163-72. 10.1016/j.annonc.2022.10.508 - DOI - PubMed
    1. Kato K, Machida R, Ito Y, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet 2024;404:55-66. 10.1016/S0140-6736(24)00745-1 - DOI - PubMed

LinkOut - more resources